Weekly Analysts’ Ratings Changes for 10x Genomics (TXG)

A number of firms have modified their ratings and price targets on shares of 10x Genomics (NASDAQ: TXG) recently:

• 12/15/2025 – 10x Genomics had its price target raised by analysts at Barclays PLC from $17.00 to $22.00. They now have an “overweight” rating on the stock.
• 12/11/2025 – 10x Genomics was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “cautious” rating.
• 12/11/2025 – 10x Genomics had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a $18.00 price target on the stock.
• 12/8/2025 – 10x Genomics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – 10x Genomics had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $20.00 price target on the stock, up previously from $17.00.
• 12/1/2025 – 10x Genomics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – 10x Genomics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/15/2025 – 10x Genomics was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/11/2025 – 10x Genomics had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/11/2025 – 10x Genomics had its price target raised by analysts at Piper Sandler from $15.00 to $19.00. They now have a “neutral” rating on the stock.
• 11/10/2025 – 10x Genomics was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 11/7/2025 – 10x Genomics had its price target raised by analysts at Canaccord Genuity Group Inc. from $16.00 to $19.00. They now have a “buy” rating on the stock.
• 11/7/2025 – 10x Genomics had its price target raised by analysts at JPMorgan Chase & Co. from $13.00 to $15.00. They now have a “neutral” rating on the stock.
• 11/7/2025 – 10x Genomics had its price target raised by analysts at UBS Group AG from $13.00 to $14.00. They now have a “neutral” rating on the stock.
• 11/7/2025 – 10x Genomics had its price target raised by analysts at Barclays PLC from $15.00 to $17.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, insider Benjamin J. Hindson sold 8,283 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $157,377.00. Following the sale, the insider owned 432,605 shares in the company, valued at $8,219,495. This trade represents a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Adam Taich sold 11,888 shares of 10x Genomics stock in a transaction on Monday, November 24th. The stock was sold at an average price of $19.00, for a total value of $225,872.00. Following the sale, the chief financial officer owned 297,385 shares of the company’s stock, valued at approximately $5,650,315. This trade represents a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 33,432 shares of company stock valued at $635,208 in the last quarter. 10.03% of the stock is owned by insiders.

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.